Twitter | Search | |
Search Refresh
Sachin S Jun 22
Market Size, Share and Global Trend By Therapy Area (Oncology, Blood, CNS, Endocrine, Cardiovascular, Respiratory, Immunomodulatory), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Geography Forecast till 2025
Reply Retweet Like
Sachin S Jun 22
Market to Reach US$ 294000 Mn by 2025, Increasing Development of Oncology-related Orphan Drugs to Dri...
Reply Retweet Like
SMi Pharma 💊 Jun 19
A great chance to meet Co-Chairs: Rick Thompson (Findacure) and Mike Page (Alexion Pharmaceuticals) at SMi’s & Conference on 15th-16th Oct 2019 in London. £300 SAVING for early birds, register online at
Reply Retweet Like
Nikki Margaretos May 20
Today I am presenting on patient access to orphan drugs at
Reply Retweet Like
Ancel·la Santos May 25
“The prices of new orphan drugs are rising so high that, taken together, they threaten the financing of all other types of health care”
Reply Retweet Like
Better Science Better Health Jun 11
EU Patient organisations report that medicines developed using the incentives from the OMP Regulation have significantly improved patients’ health and quality of life. However the access to care and treatment remains a concern
Reply Retweet Like
SmithSolve Jan 17
The Rare Collective has launched its LinkedIn page! These trusted experts in help companies navigate the development & commercialization of . Follow The Rare Collective for insights & updates:
Reply Retweet Like
Siobhan Bourke Feb 25
Thanks for having me . Three very different and interesting aspects of rare diseases discussed.
Reply Retweet Like
EUCOPE Apr 12
Gene & cell therapies are costly. How to ensure have access to these treatments whilst sustaining a healthy environment for R&D? We have some ideas...
Reply Retweet Like
Delphine Roulland Feb 13
Great kickoff of symposium by . 1- we are not faced w/ a tsunami of putting healthcare budgets @ risk 2-there are system failures & misconceptions hampering 3- a bold proposal on increased EU cooperation!
Reply Retweet Like
Ana Mingorance Feb 12
"The value of a human life is infinite, but our healthcare budget isn't" Because of that, this hospital will make cheap versions of expensive orphan drugs. Dangerous territory... if done at a larger scale, we might simply not have more .
Reply Retweet Like
Mother of Sameer Ahmad Feb 16
Are unaffordable life saving innovations serving their purpose? A video by highlighting the unfair pricing of
Reply Retweet Like
Wiebke Junge Feb 28
shows us why European is so important in : It brings better & faster access to , & , provides incentives for developing & enhances collaboration through . 🇪🇺🧪👩‍⚕️👨‍⚕️
Reply Retweet Like
Candice Tang Feb 28
Today is ! While much progress has been made in the diagnosis and treatment of rare diseases, there are still many barriers preventing from entering the market. Learn more about this topic in my new article:
Reply Retweet Like
IQVIA Asia Pacific Jun 20
Emerging companies are now able to develop without the need to partner or be acquired, allowing them to increase their pipeline share in the fastest-growing areas of and . Download the IQVIA Institute report:
Reply Retweet Like
ordiusa Mar 13
Register today for the rare and conference Lets Build collaborative bridges to accelerate therapies for April 13 - 15, 2019 New Delhi, India.
Reply Retweet Like
Myositis Support May 16
We explain and highlight a personal account of how one patient fought the insurance company trying to deny a medication for myositis. Read full story at
Reply Retweet Like
EVERSANA Apr 11
Our CEO Jim Lang is moderating a panel discussion at the World Orphan Drug Congress tomorrow. The EVERSANA team hopes to see you there!
Reply Retweet Like
ICON Plc Jan 25
ICON's trials have led to the development of 19 in the past 3 years. Learn more about our relative experience, expertise and therapeutic area innovations in this short clip
Reply Retweet Like
Better Science Better Health Jun 21
PODCAST Better Science, Better Health: VC Peter Young’s Opinion on Trump’s International Reference Pricing Plan ->
Reply Retweet Like